Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNRNYSE:CCMNASDAQ:MGRXNASDAQ:MRAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNRBurning Rock Biotech$3.69+3.8%$3.08$2.18▼$7.90$39.60M0.7523,408 shs8,696 shsCCMConcord Medical Services$5.79+3.0%$6.90$3.80▼$10.90$25.13M-0.916,135 shs2,300 shsMGRXMangoceuticals$1.49+1.7%$1.81$1.32▼$7.66$7.68M2.4218,693 shs9,767 shsMRAIMarpai$1.27-5.9%$1.28$0.40▼$1.68$21.00M4.6818,394 shs2,838 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNRBurning Rock Biotech+4.44%+11.16%+21.55%-1.23%-42.21%CCMConcord Medical Services-5.03%-1.40%-19.57%+32.91%-46.19%MGRXMangoceuticals-5.50%-3.95%-28.43%-8.75%-97.92%MRAIMarpai-5.93%-5.93%-6.62%+41.11%+62.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNRBurning Rock BiotechN/AN/AN/AN/AN/AN/AN/AN/ACCMConcord Medical Services0.8418 of 5 stars0.05.00.00.00.01.70.6MGRXMangoceuticals0.8336 of 5 stars0.05.00.00.00.01.70.6MRAIMarpaiN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNRBurning Rock Biotech 0.00N/AN/AN/ACCMConcord Medical Services 0.00N/AN/AN/AMGRXMangoceuticals 0.00N/AN/AN/AMRAIMarpai 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNRBurning Rock Biotech$70.67M0.56N/AN/A$7.39 per share0.50CCMConcord Medical Services$52.60M0.48N/AN/A$51.05 per share0.11MGRXMangoceuticals$511.08K15.02N/AN/A$4.30 per share0.35MRAIMarpai$34.87M0.60N/AN/A($1.72) per share-0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNRBurning Rock Biotech-$47.49M-$1.89N/A∞N/A-45.41%-38.33%-25.34%N/ACCMConcord Medical Services-$42.23MN/A0.00∞N/AN/AN/AN/AN/AMGRXMangoceuticals-$8.71M-$4.64N/A∞N/A-2,191.76%-72.81%-66.58%8/13/2025 (Estimated)MRAIMarpai-$28.75M-$1.82N/A∞N/A-85.70%N/A-100.23%8/5/2025 (Estimated)Latest MGRX, BNR, CCM, and MRAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/6/2025Q1 2025BNRBurning Rock BiotechN/A-$0.17N/A-$0.17N/A$18.34 million5/15/2025Q1 2025MGRXMangoceuticalsN/A-$1.29N/A-$1.29N/A$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNRBurning Rock BiotechN/AN/AN/AN/AN/ACCMConcord Medical ServicesN/AN/AN/AN/AN/AMGRXMangoceuticalsN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNRBurning Rock BiotechN/A3.022.76CCMConcord Medical Services1.670.460.45MGRXMangoceuticalsN/A0.120.12MRAIMarpaiN/A0.820.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNRBurning Rock Biotech30.03%CCMConcord Medical ServicesN/AMGRXMangoceuticals56.72%MRAIMarpai49.75%Insider OwnershipCompanyInsider OwnershipBNRBurning Rock Biotech30.30%CCMConcord Medical Services46.50%MGRXMangoceuticals16.00%MRAIMarpai61.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNRBurning Rock Biotech1,39010.76 million7.50 millionNot OptionableCCMConcord Medical Services9704.34 million2.32 millionNot OptionableMGRXMangoceuticals35.17 million4.34 millionNot OptionableMRAIMarpai15016.53 million5.61 millionNo DataMGRX, BNR, CCM, and MRAI HeadlinesRecent News About These CompaniesEarnings call transcript: Marpai posts improved Q1 2025 results amid cost cutsMay 17, 2025 | uk.investing.comMarpai, Inc. Reports Q1 2025 Financial ResultsMay 15, 2025 | tipranks.comMarpai targets cash flow positivity in 2025 with cost reductions and leadership changesMay 15, 2025 | msn.comMarpai, Inc. (MRAI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comMarpai appoints new COO to accelerate growthMay 15, 2025 | uk.investing.comMARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTSMay 14, 2025 | prnewswire.comMARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICERMay 13, 2025 | prnewswire.comMarket Access RICI Agriculture UCITS (MRAI)May 8, 2025 | investing.comMARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTSMay 7, 2025 | prnewswire.comMarpai, Inc. to Present at the Planet MicroCap Showcase Las VegasApril 15, 2025 | prnewswire.comMarpai targets profitability in 2025 with new initiatives and strategic partnershipsMarch 27, 2025 | msn.comMarpai, Inc. (MRAI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comMARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTSMarch 26, 2025 | prnewswire.comMARPAI TO HOST WEBCAST ON MARCH 27, 2025 TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTSMarch 20, 2025 | prnewswire.comMARPAI ACCELERATES HEALTHCARE TRANSFORMATION WITH EMPARA COLLABORATION, LAUNCHING UNIFIED HEALTH ENGAGEMENT PLATFORMMarch 18, 2025 | prnewswire.comHealth In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded SolutionsJanuary 22, 2025 | prnewswire.comMARPAI ANNOUNCES SECOND TRANCHE OF NON-DILUTIVE GROWTH FUNDING WITH UP TO $5 MILLION FROM JGBJanuary 6, 2025 | prnewswire.comMARPAI ANNOUNCES PRICING OF $700,000 PRIVATE PLACEMENTDecember 5, 2024 | prnewswire.comMARPAI ANNOUNCES GENERAL UPDATES FOR Q4November 26, 2024 | prnewswire.comMarpai, Inc. Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGRX, BNR, CCM, and MRAI Company DescriptionsBurning Rock Biotech NASDAQ:BNR$3.69 +0.13 (+3.76%) As of 10:20 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.Concord Medical Services NYSE:CCM$5.79 +0.17 (+3.02%) As of 09:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.Mangoceuticals NASDAQ:MGRX$1.48 +0.03 (+1.71%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.Marpai NASDAQ:MRAI$1.27 -0.08 (-5.93%) As of 07/7/2025 03:41 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.